Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
Open Access
- 22 February 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 12, 624052
Abstract
Since December 2019, the coronavirus 2019 (COVID-19) pandemic has rapidly spread and overwhelmed healthcare systems worldwide, urging physicians to understand how to manage this novel infection. Early in the pandemic, more severe forms of COVID-19 have been observed in patients with cardiovascular comorbidities, who are often treated with renin-angiotensin aldosterone system (RAAS)-blockers, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), but whether these are indeed independent risk factors is unknown. The cellular receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the membrane-bound angiotensin converting enzyme 2 (ACE2), as for SARS-CoV(-1). Experimental data suggest that expression of ACE2 may be increased by RAAS-blockers, raising concerns that these drugs may facilitate viral cell entry. On the other hand, ACE2 is a key counter-regulator of the RAAS, by degrading angiotensin II into angiotensin (1-7), and may thereby mediate beneficial effects in COVID-19. These considerations have raised concerns about the management of these drugs, and early comments shed vivid controversy among physicians. This review will describe the homeostatic balance between ACE-angiotensin II and ACE2-angiotensin (1-7) and summarize the pathophysiological rationale underlying the debated role of the RAAS and its modulators in the context of the pandemic. In addition, we will review available evidence investigating the impact of RAAS blockers on the course and prognosis of COVID-19 and discuss why retrospective observational studies should be interpreted with caution. These considerations highlight the importance of solid evidence-based data in order to guide physicians in the management of RAAS-interfering drugs in the general population as well as in patients with more or less severe forms of SARS-CoV-2 infection.Keywords
This publication has 187 references indexed in Scilit:
- Role of Circulating Angiotensin Converting Enzyme 2 in Left Ventricular Remodeling following Myocardial Infarction: A Prospective Controlled StudyPLOS ONE, 2013
- LPS-Stimulated Cytokine Production in Type I Cells Is Modulated by the Renin–Angiotensin SystemAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Ventilator-Induced Inflammatory Response in Lipopolysaccharide-Exposed Rat Lung Is Mediated by Angiotensin-Converting EnzymeThe American Journal of Pathology, 2010
- Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibitionClinical Science, 2009
- Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical OutcomesJournal of Cardiac Failure, 2009
- Regulation of ACE2 in cardiac myocytes and fibroblastsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptidesAmerican Journal of Physiology-Cell Physiology, 2008
- Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart FailureJACC, 2008
- Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase PathwayThe American Journal of Pathology, 2008
- Pathology and Pathogenesis of Severe Acute Respiratory SyndromeThe American Journal of Pathology, 2007